TASI 8150 · Insurance · ACIG
Statement of Changes in Equity
H1 / Q2 2023Equity movements
| Movement | Total equitySAR thousands |
|---|---|
| 2023 equity movements | |
| Balance at 1 January 2023 as previously reported | 162,311 |
| Transition adjustment on initial application of IFRS 17 | (11,094) |
| Transition adjustment on initial application of IFRS 9 | 37,693 |
| Restated balance at 1 January 2023 | 188,910 |
| Sale of FVOCI investments | - |
| Net income attributable to shareholders | 14,063 |
| Total comprehensive income for the period | 14,063 |
| Balance at 2023-06-30 | 202,973 |
| 2022 equity movements | |
| Balance at 1 January 2022 as previously reported | 32,036 |
| Transition adjustment on initial application of IFRS 17 | (6,856) |
| Transition adjustment on initial application of IFRS 9 | 34,830 |
| Restated balance at 1 January 2022 | 60,010 |
| Change in fair value reserve on available-for-sale investments | - |
| Increase in share capital through rights issue | 150,000 |
| Net loss attributable to shareholders | (33,612) |
| Total comprehensive income (loss) for the period | 116,388 |
| Balance at 2022-06-30 | 176,398 |
The equity statement reports a different restated January 2023 opening balance from the balance sheet and presents prior-period OCI differently from the comprehensive income statement. Values are shown as published in each statement. Published equity and OCI presentation · Page 8 ↗